Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Aug 2022

Ou Sai-Hong Ignatius, Jänne Pasi A, Leal Ticiana A, Rybkin Igor I, Sabari Joshua K, Barve Minal A, Bazhenova Lyudmila, Johnson Melissa L, Velastegui Karen L, Cilliers Cornelius, Christensen James G, Yan Xiaohong, Chao Richard C, Papadopoulos Kyriakos P

Abstract excerpt

PURPOSE: Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non-small-cell lung cancer, colorectal cancer, and other solid tumors harboring the KRASG12C mutation. MATERIALS AND METHODS: Patients with advanced KRASG12C-mutant solid tumors were treated with adagrasib 150 mg orally once daily, 300 mg once daily,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Dose-Response Relationship, Drug

Share to Fatigue

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 35167329
DOI: 10.1200/JCO.21.02752
PMCID: PMC9362872

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).PMID 35167329Read ↗

Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.Semantic proximity Read ↗

First Approval of Adagrasib for the Treatment of Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Safety and Intracranial Activity of Adagrasib in Patients With KRASG12C-Mutated Non–Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case SeriesSemantic proximity Read ↗

Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.Semantic proximity Read ↗

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C MutationSemantic proximity Read ↗

Adagrasib: First Approval.Semantic proximity Read ↗

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.Semantic proximity Read ↗

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.Semantic proximity Read ↗

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.Semantic proximity Read ↗

Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.